Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 461

1.

American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW; American Joint Committee on Cancer..

J Clin Oncol. 2007 Feb 10;25(5):507-12.

PMID:
17290058
2.

Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.

Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM.

Ann Surg Oncol. 2008 Oct;15(10):2894-902. doi: 10.1245/s10434-008-0084-y.

PMID:
18663531
3.

The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system.

Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V; American Joint Committee on Cancer staging system..

J Thorac Cardiovasc Surg. 2006 Dec;132(6):1374-81.

4.

Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP.

Ann Surg. 2009 Mar;249(3):392-6. doi: 10.1097/SLA.0b013e3181949e9f.

PMID:
19247024
5.

Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.

Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ.

Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5.

PMID:
11789772
6.

Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?

Hughes R, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M, Ashford R, Harrison RA, Livingstone JI, McDonald PJ, Meyrick Thomas J, Mitchell IC, Northover JM, Phillips R, Wallace M, Windsor A, Novell JR.

Int J Colorectal Dis. 2006 Jan;21(1):11-7.

PMID:
15864605
7.

Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.

Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL.

Ann Thorac Surg. 2010 Sep;90(3):884-90; discussion 890-1. doi: 10.1016/j.athoracsur.2010.03.116.

PMID:
20732513
8.

Proposed modification of nodal status in AJCC esophageal cancer staging system.

Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG.

Ann Thorac Surg. 2007 Aug;84(2):365-73; discussion 374-5.

PMID:
17643602
9.

Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.

Torres C, Turner JR, Wang HH, Richards W, Sugarbaker D, Shahsafaei A, Odze RD.

Cancer. 1999 Feb 1;85(3):520-8.

PMID:
10091725
10.

Does neoadjuvant chemoradiation downstage esophageal carcinoma?

Slater MS, Holland J, Faigel DO, Sheppard BC, Deveney CW.

Am J Surg. 2001 May;181(5):440-4.

PMID:
11448438
11.

Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases.

Lee PC, Port JL, Paul S, Stiles BM, Altorki NK.

Ann Thorac Surg. 2009 Jul;88(1):186-92; discussion 192-3. doi: 10.1016/j.athoracsur.2009.03.079.

PMID:
19559222
12.

Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.

Saha AK, Sutton C, Rotimi O, Dexter S, Sue-Ling H, Sarela AI.

Ann Surg Oncol. 2009 May;16(5):1364-70. doi: 10.1245/s10434-009-0396-6.

PMID:
19252949
13.

Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.

Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R.

Ann Surg Oncol. 2010 Apr;17(4):1159-67. doi: 10.1245/s10434-009-0862-1.

PMID:
20140529
14.

The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.

Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT.

Cancer. 2006 Mar 1;106(5):1017-25.

15.

En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.

Rizzetto C, DeMeester SR, Hagen JA, Peyre CG, Lipham JC, DeMeester TR.

J Thorac Cardiovasc Surg. 2008 Jun;135(6):1228-36. doi: 10.1016/j.jtcvs.2007.10.082.

16.

Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus.

Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, Ajani JA.

Cancer. 2005 Oct 1;104(7):1349-55.

17.

ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus.

Brabender J, Vallböhmer D, Grimminger P, Hoffmann AC, Ling F, Lurje G, Bollschweiler E, Schneider PM, Hölscher AH, Metzger R.

J Gastrointest Surg. 2008 Nov;12(11):1815-21. doi: 10.1007/s11605-008-0668-7.

PMID:
18769985
18.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2.

PMID:
19418101
19.

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.

Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML.

J Natl Cancer Inst. 2005 Aug 3;97(15):1137-42.

20.
Items per page

Supplemental Content

Support Center